Comment by wwasilev

This is just getting started. VKTX just reported phase 1 results of their GLP1/GIP dual agonist. It appears effective in reducing liver fat (NASH), plasma lipips and weight. The side effects were mild to moderate.

TERN and GPCR are also in the game.